Fate of Transcept's sole clinical project hangs in balance after missed endpoint
This article was originally published in Scrip
Transcept Pharmaceuticals will outline the future - or demise - of TO-2061 (ondansetron oral tablets 0.5mg and 0.75mg) in early 2013 in response to the add-on therapy's missed primary efficacy endpoint in a Phase II clinical trial, which looked for an improvement in obsessive compulsive disorder (OCD) symptoms versus placebo.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.